NasdaqGM:TRVIPharmaceuticals
Trevi Therapeutics (TRVI) Valuation Check After 200% YTD Rally and IPF Cough Hopes
Trevi Therapeutics (TRVI) has quietly turned into one of the market’s bigger biotech gainers this year, with the stock up sharply over the past 3 months as traders reassess its pipeline potential.
See our latest analysis for Trevi Therapeutics.
Zooming out, that surge fits into a powerful run, with Trevi’s year to date share price return above 200 percent and a one year total shareholder return above 400 percent, suggesting momentum is still building as investors re-rate its IPF cough...